Our portfolio company ASPIVIX SA announced last week the completion of and interim analysis results from its Phase I first-in-women trial. The two-phase ADVANCE Women trial is assessing the usability, efficacy, and safety of the investigational CAREVIX, the innovative device designed as a modern and gentler alternative. Warmest congratulations on your achievement, ASPIVIX!
ASPIVIX Phase I news release_FINAL
About HEMEX
HEMEX is a CRO providing clinical services to European biotech and medtech companies, assisting them throughout the clinical development process to ensure that products reach the market swiftly. Located in the Basel region, a major life sciences hub, and with offices in Germany and Benelux, we are well positioned to serve small and medium enterprises (SMEs) with multinational clinical projects. The comprehensive package of services we provide includes clinical operations, quality management, regulatory guidance, grant writing services, and fundraising options. At HEMEX, we guarantee fast and clear communication, local accessibility, and transparency to meet the objectives of our clients. For more information, visit https://hemex.ch/